Slide 1: NeoStem Investor Presentation August 2012
ZLOz ysnbny SON -LYIN SSAN UOI}E}JUIS91d JO}S9AU| W21S@ON s30Inuas AavesH 7120
Slide 2: Forward-Looking Statements
Jeujoumn pi lv w | uo uo yodey | se Jo9}N0 ‘jUaLU|ouUa ‘Bt Bulpnjout ‘paziieas ful yo sjyousq ano Jo adoos ou TT 29 rit uy Ajdusoo 40 ‘SuOEaYRIeS 10 ‘ssuoqey!pes00e ‘sasueol) jeyuewuseno6 ‘ajeudosdde ureygo 0} Ayuge sno (lA) ‘jouoo y i Auge sayjaun (0) ‘pated © faige odd ly pue “100-4 49) SIE r - Au
Slide 3: What is NeoStem
suoljeiedo jseog json puejysey + Ajuaioiyje syonpoid aunyoesnuew 0} Aj pue souaiiedxe AlojyeinBai Buodjs ym wee} JuswebeueW psouaedxy saluediuoo Adesay} |[99 Jo ,OUA S,o4M,, SHoddng - JapiAoid aolAjas HBuimoi6 ‘Buyesoueb anusna ‘aayedwoo AjyBiy} isnq (OINGO) Bur 4 pue Jojaaap yoesjUu02 Adesay} ||2D
Slide 4: Technology, operations and commercial development
Seah 3. ABojouyDe ee aS) ee! r- WeISsoN” — ay Ise eeu isnd@ Resa suoiesado jelozawiw05 quawdojaneq Ades] ||29 W2}S8ON
Slide 5: Expanding the portfolio of products
S]UAI|9 OO] J@A0 Bulnies Woy soUstedxy suonesedo jeloseuwu0o ApIMpLOM Buryoune] 10} WUOe\q juowdojanap yonpod Juaioyja ysoo ‘Na}se4 juatudojansp yonpoid Joy ys UOT 7 i} eseud YyBnosy) eep! wol4 — a}Aosowy S1O™ pue siojebisaaul ‘S]SIJUDIOS JO SUBS} SSE[O PON oljojiod qj Buipuedx3 sjonpoid anjea uBiy
Slide 6: Therapy services: contract development and manufacturing
sjuswebebue peziwojysno yuowauinbal AsoyeinBau ebeueyy yuawdojanep d] sousiBo} Ip pue Bul. >jNUBLU ‘So|WUOU0D9 aSIWI}dOQ, s]elu} je2d!ul}9 Jo Woddns pue uBbisap 84} YIM jsIssy Ayiqeseduioo ulejulew pue ysijqe}sy Aousjod pue uojezueyjoeseyo yonpoid aye16a}u) syonpoid sonedeseu} OJUI BOUAIDS JO UOISJB
Slide 7: Manufacturing experience and cell therapy types
jeuounan, saseasip snoiaayul jeuids saseasip 99uUaD, aeinosenoipsed, ‘A30|09U9, suones|ddy uonesauasay quawasejday . . / onadesayl suonna|es vé GD sque|duy] Xue [29 souesqua Ge uojsuedxg OnlA-x3 uoneanoy areséy uoneinsdeou3 Yonnpul []29 auPjouD x1 8uaD saangind 4e(Nn|j25 S9SS8I0Jd ||AD SI]99 wars S3
Slide 8: Cell therapy manufacturing capacity
r(. Se oie CS SLIISCG” SMS cos ND Ep Jojnijequnwi| MKT e vd ww” ‘speeu Bulnjoeynuew 194} Jo Wed JO [Je 10, seolses Bounos}no aoeds Adesauy} ||89 ay} Ul SelUedWOd |JeWs pue ebie7 + juawdojenap Adesau} Jo} Buuinjoeynuew ajeos abe] ||99 J2UJOJU! JO} S}SOO JeMo] Se|qeuUe sjUe! Ayoedeo Buunjoejnuew qo UY
Slide 9: Cardiac program clinical data
. — ai ee 3 ie * = oy : SOL-86 (L)L9} ‘Jewnop peo} ueHeWy ‘L10z 12 18 WV lNAAND uojeroossy wee} UeoLEUY :se0ual8}04 sso] a}AooAwolpsed anissaiboid pue sisojdode si (Aqualoyjnsul JeinoseAosoiw) uoisnied ayenbapeul jo souanbasuce vy yyeep aunyeudig + aunjiey Weey eaysebuoD uonoeyul jelpseookui yusunos
Slide 10: Mobilized cells mechanism
sisouabolbueocou Buronpul pue sjoayo euloesed yBnoiuj sisojdode Bunusaaid ‘auoz Jouejul-ad au} 0} d14dou} eue s|/89 pezijiqow ay | $||20 +VYOXD+VEAO SEZIIIQoW Yorum |-4as 40 siseyjuxs seonpul 4/H au0z youejul-lad au} ul eIxodAy Aq peonpu! s! (4H) [eubis ssoysip y :Buljapowas Je|noWJU9A JUBAJd 0} ONs
Slide 11: Cardiac program trial design
Peniesaig eros ueaH sspuarxg 2u0z pe}oveyU| qUOUIEALL LOO-NWW UW = UAUEAL L00-YINV INOW oxeyuyasog S129, 0} syUOW 9Z0z UENO) sjue}ed poujew pue JaneW Jo UoNIsodwWos YIM dq) JUBUILOG MOpUIM JUBWUIJEA4} BIqIXEY SMO|IE B}I| JOYS NOY ZZ {elu} JeolUIJo | @SeYd Ul PeUILJe}ep pjoyselyy esoq (apei6 jeonnsoe
Slide 12: Treatment protocol and cell separation
i a ‘vul 243 0JUI LONDaful sou uopeiedes 1189 4NoH 8-9 JoujUod snsJan (We juawjea.}) yonpoud |j90 Bulurejuoo +VYHOXD+VEAD © 40 SII99 NGL JO ‘OL ‘G Jo uoIsnyul AreuoJooesu] © 96) %0G 5 (43) ABojouyos} Ayeyatidoid JUSS} OJ 2} sI juayed ‘(Bujueys ysod sunoy uojoey uonoale J] 6 juajs e SaAla09y oe Bulsn
Slide 13: Trial results
oezt- ozor o'ves Sie WSL 8798 e'se9 9866 Sil@D WOL elt O?2L raza Syl+ gele ose @BUeYD % eyeq syuowg eur aseg poyoo (uoisnyedodAy) SSLU ‘000% 008 oor oori0eo” ~ * = 00 cov ____s18® vedo exsou 40s 0 2800 = X'SS1U V =A 90-30% 9013052 901300 ——a0ra0ST - oor $1189 HEC A[IGow | AAS JO 850q = x 'SSEW AT %
Slide 14: Summary of results
901-86 (1)L9L ‘jewnor Ployseuy enogy peel UeOueUIY ‘LL07 1238 WY 1wnAsnD, cal or | Eu | Plouseuus mojeg v% wy wo 74 yuow 9 SUINIOA 2110}8Kg pug plousesyL snogy Or s yonuop ob Le wey | [%p'6+ juewenciduy | a a eis og | PIOUS More uoyoe14 uoNoe/3, T T %OE quow 9 ploysesy| saoqy Ov uogoes4 uonzely ul d
Slide 15: Cardiac events and safety
‘000! _ ZLOZ/6/8 — [eUBIs Ajayes OU SULYUOS MAINAJ 5, GINS MealAey Ajayes S]USA2 |eOJUIJO JBYJO pue <10D ‘UoHOUNY oeIpied ‘UOISN}eq :JUA@LU|JO1UA Jo UOa|diuoS Jaye SyJUOW XIS jNOpeey e}eq }SII4 sayeys poyun AydesBoag sjuayed 9g, s}oefgns jo sequinn Joujuoo ogase|d weys 0} JUaW}ee,} |:| peziwopueYy U
Slide 16: Submission
L102 uolssiuqns yg uonejusseld e}eq || 8seUd xeIW 008 = squalted DOvA YAY S78 ine ES Cia J xeW 008 = siuaned OPT = Sous feu. sug mee oe O9T = siuoned See Se 0S = Sauls [eu pwn pwn use oust w *lelelele zlt)*]elz]e]° vPelels dD] do} do] dv] od v| odo] vo] do] od] od] vd dD] dD] DID | stoz | oz | JOJBW
Slide 17: Regulatory pathway and pricing
000'9¢-Sz$ Jo eBue, payewnse qSy sisfjeue Byep SOV UO paseg + OUG-SW [eHlu! Jo Hed oq Aja»! {I!M UOIsNyU! pue (HOS) ISPAUEH [19D WEIS + SUJUOW ¥Z 0} Z| Bye} UD BpooD-f e Bulnleoas pue Bully — Asenuer ul Je8f & 80u0 pajuelg — @pO0O-f |EWUO} e andes 0} PIaN uonesjsiuiupe ye einpascid au} JO} pasunquul
Slide 18: Additional potential indications
Aunful uresq ojwayos| BIWAYOS! ul] [2D aunylej Weay salyseBuoD IWy-}sod elwayos: UeDOAW DULY + eIWayos! Buikyepun woy Bunjnses Suoi!PUCS JaUjO 0} paljdde oq ued wso}e|d LOO-YINIV Aoualoyjnsul Jejnosea ysoq :Aunful sejnosea Auy :uoeoipul *ZL.0Z/¢/) penss| :02¢'880'8 S'N aye] pue Aiea [WW ISOq ‘OeIPIe
Slide 19: Autoimmune and neurological disease program
698-858'081 ‘8002 ABojounuiuu| Jo feusnop ‘Je 49 Ong-UeIP “YEYD (1 sewoydush| pue sequiaynay 404 que|dsuen jja9 ways 2IeUaZO|Ie (aHa9) aseasia uy8aN qoy a quaunean ysod onsiouel SYIUOW ¢-y 3e UOISsIUas jeDIUN)D UI a1am dnosd ues 1e ejUsoyted Jo Auisionlun, auoysanig Aaayar 40 quaunneasn Jo %08 ‘saso
Slide 20: Preclinical research and cardiac data
“aBewep jo seaie ow ayesB0.U! ue ayesius ueo aka ayy ut s135A paI2afu ssaseasip e120 UW Jo Buljeay payensuowag Buyjeay punom Jev@1@S Jo Japou! asnow e ut auog uewnYy “AUN pace} ‘aynyNsUl uexyse) uexeWwey youeasay 3Aq suadayos “4G pue BUNOA |aeYIN “IC ty 4aquaa, Jeo1pay swell 42304 eBueley JUaIUIA “4
Slide 21: Government grants
diysuoyejas e paysiqejse Ajsnoinaid @AeY OM SUONNIYSU! YUM - QOO'OOS'EL$ :PEyWwigng sjuesd [e}OL 000'sge' L$ :Bulpued syuesn je}0, - 00S‘0EL'e$ :pepaemy sjUeID eAOW 12}0L - youn uaa wwiaz't$- | oseud OWN Ua 000'002$ - 1 aseud ‘Spunoy 210149 3808 0) $73SA Buisn $((aoa) esuajeq yo juauniedag (uuze) se
Slide 22: Intellectual property
UOI}EIOSI |]99 W9}S uonelpey SJAPJOSIP JejN9O Buljeay punopyy a1pedouO ABojoipseg ABojounuiwj + SAPNIOU! qd] $,LUA}SOON JO SNdO} Adesay} ||8D + Bolly UNOS pue jaeJs| ‘eljeasny ‘els ‘edouny ‘eovawiy YON sepnjou! sBuljy jo ujpesiq s1ydeiBoag SWIe|D SpoujeW pue Jaye Jo UOTIsSodwoD Bulpuad sarjiuey yuay
Slide 23: Key financial information
sepenb ply} au} ul a{1z Jo ajes WoL spasd0id yseo peyadxy , ZLOz ‘O€ unr 0} JUeNbasqns penieoa! asiosexa JUeLIEM pue sajes AyInba paiajsiBaJ-UOU WO SPeBd0ld ¢ UOHEIIDUCIAL dYWO-UON 0} dW 404 xIpuaddy seg z suoijesado Buinujuos Woy senuansy , whe (99° L$ Jo aod asiosaxe jueeM ‘Bae) we'gg (Ge Lg JO so
Slide 24: NeoStem common stock and warrants
( Buryeut ay} ul) SsolD, uapjog ajqnog / wnuyeld vii £eP-0044 él ynoyeag ae saNm 4903S UOUIUOD “DUI ‘we|SOON Bulpesl }e1uYye1 SEN
Slide 25: In process
ssaooid ul Jo pasodold , OLS card UOIIIN €°ZOLS 12301 — SUOITIN UW! ZL/01/8 UBNowuyL pesiey spun4 e Les ees LGL$ Sts uoqeonpe 1/20 we}s ynpe 10} ueonen YUM diyssouped seak g uebag (@f13 40 %LS) H@9 pauinboy 62s seg “oul ‘WaISoeN pauinboy leoIpew Il 84d uoisuedxy, paunboy spaysanig Gi s}UsWdAsIyoY UO
Slide 26: Summary
SUOHOBSURL} WRI SAY. paja|dwioo A\jnjsseoong aoualiedxe soueUy ge Buunyoesnuew ‘AuojeinBau ‘juewudojenep pue youeesed yjIM Wes} juswWebeUeYY - aynoexq ued Jey! diyssopesq saluedwoo Adesdu} [199 JO ,OUM S,OUA,, UJIM S}usWaesbe YBnou} Yoeosdde jo uoHeplle\, souaedxe AuojeinBes yjim wee} juswebeuew Bu0
Slide 27: Appendix
XIGNAddV
Slide 28: Consolidated net loss to non-GAAP reconciliation
(e6z'z69'6) $ seBseyd yseo-uon Bulpnjoxg sso7 Jan payepyjosuoD, oos‘eez asuedxe yqep peg (ZbS‘L LL) Auuigely eageauap jo anjea ayey ul soBueyD 9e1'7Z8 3809 aouenss| pue junodsip 490}s pauajaid jo uoneZPOWY eLL'vle uojezqjiowe pue uojeiseidaq LLo‘sss‘e panss! sjuessem pue suondo 4903s ‘y90}s UOWIIOD
Slide 29: Contact Information
WOd'Wa}sosuMU}wss :|!ewWy vLLb-v8S (ZZ) seuoud O49 9 UeULeYD VIN ‘CIN ‘ujIWUS UIqoy WOd°W98}SOSU MMM SGN :LMIN ASAN “u] ‘Wda}G08N UOHJEWIOJU] JORJUOD